The importance and merits of greater patient involvement in medicines research and development (R&D) are commonly acknowledged and are thought to offer benefits for all involved parties. It helps to improve discovery, development, and evaluation of new effective medicines, based on the collaborative identification and understanding of unmet needs, research priorities, optimization of clinical study design, outcome measures, and endpoint development. It can result in increased transparency, trust and mutual respect between patients and other stakeholders.
EUPATI Guidance for Patient Involvement in Med... - CLL Support
EUPATI Guidance for Patient Involvement in Medicines Research and Development (R&D); Guidance for Pharmaceutical Industry-Led Medicines R&D
Written by
Myrddin
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
LLR response to the proposed cuts sorry Bloodwise
Hi Nick finally got hold of the right person this is there response. Ive been busy drumming up...
Ibrutinib Slow but steady foreward movement.
Slowly things move forwards…
New Marketing Authorisation Application Submitted to EMA for...
Guidance on social distancing for everyone in the UK and protecting older people and vulnerable adults - and THAT'S ALL OF US.
From the UK Gov website.
"There are some clinical conditions which put people at even higher...
Oncology Prescribing Tied to Drugmaker Payouts
NOT specific to CLL buy then again..???
(Reuters Health) - Some oncologists may be more likely...
ABT-199 Trial experience in Australia
Following are my notes on the presentation by Andrew Roberts, to the Australian Leukaemia...
Related Posts
- Hypertension and cardiovascular events following ibrutinib initiation
Can you think off a poll that investigates an aspect of CLL life that may make a difference?- Resistance-Associated Mutations in CLL Patients Treated With Novel Agents
Statins and Ibrutinib- No evidence homeopathy is effective: NHMRC review
